OLDWICK, N.J., May 20, 2020 /PRNewswire/ -- Provention Bio, Inc.
(Nasdaq: PRVB), a clinical-stage biopharmaceutical company
dedicated to intercepting and preventing immune-mediated diseases,
today announced two changes to its board of directors.
Nancy Wysenski has been appointed
to Provention's board of directors. Ms. Wysenski, the former Chief
Commercial Officer of Vertex Pharmaceuticals, brings over 30 years
of leadership in biotechnology and pharmaceuticals, and a proven
track record in innovative therapeutic launches and corporate value
creation, including rare life-impacting diseases with high unmet
need.
"I am excited to join the board of Provention and bring my
strategic marketing, market access, and launch experience as the
Company builds out its commercial organization and prepares for the
potential launch of teplizumab," said Nancy
Wysenski. "I am looking forward to working with my fellow
directors and the management team to advance this important
treatment in type one diabetes (T1D)."
Mr. DiGiandomenico has stepped down as director after three
years of service on the board of Provention.
"The addition of Nancy to our Board confirms our commitment to
bringing our potentially game-changing teplizumab therapy to the
T1D community. I am very pleased to welcome Nancy to our board
where we anticipate that her expertise, experience, guidance and
governance will be invaluable," stated Ashleigh Palmer, Chief Executive Officer. "I
would also like to thank Anthony for the key role he has played in
the formation and growth of Provention over the past three
years."
Ms. Wysenski served as the Executive Vice President and Chief
Commercial Officer of Vertex Pharmaceuticals from December 2009 through her retirement in
June 2012. During her tenure at
Vertex, Ms. Wysenski was responsible for the launches of Incivek
and Kalydeco. Prior to joining Vertex, Ms. Wysenski held the
position of Chief Operating Officer of Endo Pharmaceuticals, a
specialty pharmaceutical company, where she led sales, marketing,
commercial operations, supply chain management, human resources and
various business development initiatives. Prior to her role at
Endo, Ms. Wysenski participated in the establishment of EMD
Pharmaceuticals, Inc., where she held various leadership positions,
including the role of President and Chief Executive Officer from
2001 to 2006 and Vice President of Commercial from 1999 to 2001.
From 1984 to 1998, Ms. Wysenski held several sales-focused roles at
major pharmaceutical companies, including Vice President of Field
Sales for Astra Merck, Inc. Ms.
Wysenski serves as a member of the board of directors of Alkermes
plc and Tetraphase Pharmaceuticals, each a publicly traded
pharmaceutical company. Ms. Wysenski formerly served as a director
for Dova Pharmaceuticals Inc., Reata Pharmaceuticals, Inc. and
Inovio Pharmaceuticals, Inc. She is a founder of the Research
Triangle Park chapter of the Healthcare Business Women's
Association and served on the Nominating Committee and National
Advisory Board of the Healthcare Businesswomen's Association.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage
biopharmaceutical company leveraging a drug development strategy
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to source, transform and develop
therapeutic candidates targeting the high morbidity, mortality and
escalating costs of autoimmune diseases. Provention's portfolio
includes PRV-031 (teplizumab), a pre-commercial-stage candidate
that has been shown to delay the onset of end-stage type one
diabetes (T1D) in at-risk individuals with pre-symptomatic disease.
The Company's portfolio includes additional clinical-stage product
development candidates currently in development for other
autoimmune diseases, including celiac disease and lupus.
Forward Looking Statements:
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements related to the anticipated value of
the addition of Ms. Wysenski to our board. These statements may be
identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based
on Provention's current expectations and actual results could
differ materially. There are a number of factors that could cause
actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, the risks listed under "Risk factors" in our annual
report on Form 10-K for the year ended December 31,
2019 and any subsequent filings with the Securities and
Exchange Commission (SEC). As with any pharmaceutical under
development, there are significant risks in the development,
regulatory approval and commercialization of new products.
Provention does not undertake an obligation to update or revise any
forward-looking statement. The information set forth herein speaks
only as of the date hereof.
Investors:
Sam Martin,
Argot Partners
sam@argotpartners.com
212-600-1902
Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-announces-changes-to-its-board-of-directors-301062264.html
SOURCE Provention Bio, Inc.